Piramal Pharma Limited (PPL) achieved a significant milestone by scoring **63** on the **2025 S&P Global Corporate Sustainability Assessment (CSA)**, marking a **15% improvement** from the previous year’s score of **55**. This performance places PPL in the **91st percentile** among pharmaceutical companies, reflecting its robust commitment to sustainability practices.
The S&P Global CSA is a respected annual evaluation that assesses the sustainability efforts of thousands of companies across various sectors. It evaluates organizations based on environmental, social, and governance (ESG) criteria, governance maturity, and long-term value creation. This assessment has become a vital tool for companies to benchmark their sustainability performance against competitors while identifying potential risks and opportunities.
PPL’s advancement in the CSA underscores its dedication to responsible operations and sustainable growth. The company’s performance is underpinned by a comprehensive four-pillared sustainability strategy that integrates ESG principles into all aspects of its business. These pillars include **Business Resilience, Quality & Excellence, Responsible Operations**, and **Stakeholder Centricity**. By focusing on these areas, PPL aims to enhance its operations while benefiting partners, patients, and the environment.
Commitment to Sustainable Practices
“Our progress on the S&P Global CSA underscores our unwavering dedication to responsible operations and sustainable growth,” said **Peter DeYoung**, CEO of Piramal Global Pharma. He emphasized that as the company continues to expand, it remains committed to excellence in all operations, contributing to a healthier future for all.
The improvements noted in this year’s assessment are a testament to PPL’s ongoing efforts to elevate its sustainability practices. A higher score not only enhances the company’s reputation but also boosts confidence among clients and global investors.
PPL operates a diverse portfolio through its various segments, including **Piramal Pharma Solutions**, a leading global Contract Development and Manufacturing Organization (CDMO), and **Piramal Critical Care**, which focuses on complex hospital generics. The company has a global distribution network spanning over **100 countries** and boasts **17** development and manufacturing facilities worldwide.
In addition to its core operations, PPL has also made strategic investments, such as a minority stake in **Yapan Bio Private Limited**, which operates in the biologics and vaccine segments. Furthermore, one of its associate companies, **Abbvie Therapeutics India Private Limited**, has emerged as a market leader in the ophthalmology therapy area within the Indian pharmaceutical landscape.
As PPL looks ahead, it seeks to leverage the insights gained from its CSA performance to further enhance its sustainability initiatives. The company’s focus on integrating responsible practices into its business model reflects a growing trend among organizations to prioritize sustainability in their operations.
For more information about Piramal Pharma Limited and its sustainability initiatives, visit their official website or follow them on LinkedIn.
